139 related articles for article (PubMed ID: 12458677)
21. Hepatic and intestinal contributions to pharmacokinetic interaction of indinavir with amprenavir, nelfinavir and saquinavir in rats.
Gao W; Kishida T; Kageyama M; Kimura K; Yoshikawa Y; Shibata N; Takada K
Antivir Chem Chemother; 2002 Jan; 13(1):17-26. PubMed ID: 12180646
[TBL] [Abstract][Full Text] [Related]
22. Multidrug resistance protein 2 (MRP2) transports HIV protease inhibitors, and transport can be enhanced by other drugs.
Huisman MT; Smit JW; Crommentuyn KM; Zelcer N; Wiltshire HR; Beijnen JH; Schinkel AH
AIDS; 2002 Nov; 16(17):2295-301. PubMed ID: 12441801
[TBL] [Abstract][Full Text] [Related]
23. Intracellular concentration of the HIV protease inhibitors indinavir and saquinavir in human endothelial cells.
Armbruster C; Vorbach H; Steindl F; El Menyawi I
J Antimicrob Chemother; 2001 Apr; 47(4):487-90. PubMed ID: 11266428
[TBL] [Abstract][Full Text] [Related]
24. Targeting SVCT for enhanced drug absorption: synthesis and in vitro evaluation of a novel vitamin C conjugated prodrug of saquinavir.
Luo S; Wang Z; Patel M; Khurana V; Zhu X; Pal D; Mitra AK
Int J Pharm; 2011 Jul; 414(1-2):77-85. PubMed ID: 21571053
[TBL] [Abstract][Full Text] [Related]
25. Efficacy, tolerance, and pharmacokinetics of the combination of stavudine, nevirapine, nelfinavir, and saquinavir as salvage regimen after ritonavir or indinavir failure.
Casado JL; Dronda F; Hertogs K; Sabido R; Antela A; Martí-Belda P; Dehertogh P; Moreno S;
AIDS Res Hum Retroviruses; 2001 Jan; 17(2):93-8. PubMed ID: 11177388
[TBL] [Abstract][Full Text] [Related]
26. Simultaneous determination of five HIV protease inhibitors nelfinavir, indinavir, ritonavir, saquinavir and amprenavir in human plasma by LC/MS/MS.
Chi J; Jayewardene AL; Stone JA; Motoya T; Aweeka FT
J Pharm Biomed Anal; 2002 Oct; 30(3):675-84. PubMed ID: 12367693
[TBL] [Abstract][Full Text] [Related]
27. Long-term effects of HIV-1 protease inhibitors on insulin secretion and insulin signaling in INS-1 beta cells.
Schütt M; Zhou J; Meier M; Klein HH
J Endocrinol; 2004 Dec; 183(3):445-54. PubMed ID: 15590971
[TBL] [Abstract][Full Text] [Related]
28. Assessment of active transport of HIV protease inhibitors in various cell lines and the in vitro blood--brain barrier.
van der Sandt IC; Vos CM; Nabulsi L; Blom-Roosemalen MC; Voorwinden HH; de Boer AG; Breimer DD
AIDS; 2001 Mar; 15(4):483-91. PubMed ID: 11242145
[TBL] [Abstract][Full Text] [Related]
29. Simultaneous HPLC assay for quantification of indinavir, nelfinavir, ritonavir, and saquinavir in human plasma.
Remmel RP; Kawle SP; Weller D; Fletcher CV
Clin Chem; 2000 Jan; 46(1):73-81. PubMed ID: 10620574
[TBL] [Abstract][Full Text] [Related]
30. Simultaneous determination of the new HIV protease inhibitor lopinavir (ABT 378) and of indinavir(1), amprenavir, saquinavir, ritonavir (ABT 538)(2) and nelfinavir(3) in human plasma by gradient HPLC.
Kuschak D; Mauss S; Schmutz G; Gantke B
Clin Lab; 2001; 47(9-10):471-7. PubMed ID: 11596909
[TBL] [Abstract][Full Text] [Related]
31. A Mathematical simulation to explain the coordinated functions of efflux and metabolism limiting the transport of anti-HIV agents across Caco-2 cells.
Patel J; Hussain A; Pal D; Mitra AK
Am J Ther; 2004; 11(2):114-23. PubMed ID: 14999363
[TBL] [Abstract][Full Text] [Related]
32. The choice of HIV protease inhibitor: indinavir is currently the best option.
Prescrire Int; 1999 Apr; 8(40):55-60. PubMed ID: 10848067
[TBL] [Abstract][Full Text] [Related]
33. Effect of coadministration of nelfinavir, indinavir, and saquinavir on the pharmacokinetics of amprenavir.
Pfister M; Labbé L; Lu JF; Hammer SM; Mellors J; Bennett KK; Rosenkranz S; Sheiner LB;
Clin Pharmacol Ther; 2002 Aug; 72(2):133-41. PubMed ID: 12189360
[TBL] [Abstract][Full Text] [Related]
34. Influence of P-glycoprotein on the transport and metabolism of indinavir in Caco-2 cells expressing cytochrome P-450 3A4.
Hochman JH; Chiba M; Nishime J; Yamazaki M; Lin JH
J Pharmacol Exp Ther; 2000 Jan; 292(1):310-8. PubMed ID: 10604964
[TBL] [Abstract][Full Text] [Related]
35. Interaction of eight HIV protease inhibitors with the canalicular efflux transporter ABCC2 (MRP2) in sandwich-cultured rat and human hepatocytes.
Ye ZW; Camus S; Augustijns P; Annaert P
Biopharm Drug Dispos; 2010 Mar; 31(2-3):178-88. PubMed ID: 20238377
[TBL] [Abstract][Full Text] [Related]
36. Enhancement of cellular uptake, transport and oral absorption of protease inhibitor saquinavir by nanocrystal formulation.
He Y; Xia DN; Li QX; Tao JS; Gan Y; Wang C
Acta Pharmacol Sin; 2015 Sep; 36(9):1151-60. PubMed ID: 26256404
[TBL] [Abstract][Full Text] [Related]
37. Effect of simultaneous versus staggered dosing on pharmacokinetic interactions of protease inhibitors.
Washington CB; Flexner C; Sheiner LB; Rosenkranz SL; Segal Y; Aberg JA; Blaschke TF;
Clin Pharmacol Ther; 2003 May; 73(5):406-16. PubMed ID: 12732841
[TBL] [Abstract][Full Text] [Related]
38. Enhanced transport of P-glycoprotein substrate saquinavir in presence of thiolated chitosan.
Föger F; Kafedjiiski K; Hoyer H; Loretz B; Bernkop-Schnürch A
J Drug Target; 2007 Feb; 15(2):132-9. PubMed ID: 17365284
[TBL] [Abstract][Full Text] [Related]
39. Transport mechanism of lipid covered saquinavir pure drug nanoparticles in intestinal epithelium.
Xia D; He Y; Li Q; Hu C; Huang W; Zhang Y; Wan F; Wang C; Gan Y
J Control Release; 2018 Jan; 269():159-170. PubMed ID: 29129657
[TBL] [Abstract][Full Text] [Related]
40. Boosting of HIV protease inhibitors by ritonavir in the intestine: the relative role of cytochrome P450 and P-glycoprotein inhibition based on Caco-2 monolayers versus in situ intestinal perfusion in mice.
Holmstock N; Annaert P; Augustijns P
Drug Metab Dispos; 2012 Aug; 40(8):1473-7. PubMed ID: 22550269
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
